MedImmune next-generation FluMist
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MedImmune has initiated a pivotal Phase III head-to-head study comparing its next-generation, refrigerator-stable formulation of its intranasal flu vaccine FluMist to the trivalent injectable vaccine, the firm says Oct. 20. FluMist is a frozen, live, attenuated trivalent vaccine. The double-blind study will enroll 7,000 children between the ages of 6 and 59 months. A bridging study is also being conducted to establish the new cold-adapted intranasal formulation (CAIV-T) as equivalent to frozen FluMist. MedImmune has already conducted two Phase III trials in 4,400 children with a history of respiratory illness or asthma; data were presented at the Pediatric Academic Societies' annual meeting in May...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.